Das Suchergebnis hat sich seit Ihrer Suchanfrage verändert. Eventuell werden Dokumente in anderer Reihenfolge angezeigt.
  • Treffer 39 von 45
Zurück zur Trefferliste

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-314637
  • While there is abounding literature on virus-induced pathology in general and coronavirus in particular, recent evidence accumulates showing distinct and deleterious brain affection. As the respiratory tract connects to the brain without protection of the blood–brain barrier, SARS-CoV-2 might in the early invasive phase attack the cardiorespiratory centres located in the medulla/pons areas, giving rise to disturbances of respiration and cardiac problems. Furthermore, brainstem regions are at risk to lose their functional integrity. Therefore,While there is abounding literature on virus-induced pathology in general and coronavirus in particular, recent evidence accumulates showing distinct and deleterious brain affection. As the respiratory tract connects to the brain without protection of the blood–brain barrier, SARS-CoV-2 might in the early invasive phase attack the cardiorespiratory centres located in the medulla/pons areas, giving rise to disturbances of respiration and cardiac problems. Furthermore, brainstem regions are at risk to lose their functional integrity. Therefore, long-term neurological as well as psychiatric symptomatology and eventual respective disorders cannot be excluded as evidenced from influenza-A triggered post-encephalitic Parkinsonism and HIV-1 triggered AIDS–dementia complex. From the available evidences for coronavirus-induced brain pathology, this review concludes a number of unmet needs for further research strategies like human postmortem brain analyses. SARS-CoV-2 mirroring experimental animal brain studies, characterization of time-dependent and region-dependent spreading behaviours of coronaviruses, enlightening of pathological mechanisms after coronavirus infection using long-term animal models and clinical observations of patients having had COVID-19 infection are calling to develop both protective strategies and drug discoveries to avoid early and late coronavirus-induced functional brain disturbances, symptoms and eventually disorders. To fight SARS-CoV-2, it is an urgent need to enforce clinical, molecular biological, neurochemical and genetic research including brain-related studies on a worldwide harmonized basis.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Peter Riederer, Volker ter Meulen
URN:urn:nbn:de:bvb:20-opus-314637
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Institut für Virologie und Immunbiologie
Medizinische Fakultät / Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):Journal of Neural Transmission
ISSN:0300-9564
ISSN:1435-1463
Erscheinungsjahr:2020
Band / Jahrgang:127
Heft / Ausgabe:9
Seitenangabe:1217-1228
Originalveröffentlichung / Quelle:Journal of Neural Transmission (2020) 127:1217–1228. https://doi.org/10.1007/s00702-020-02230-x
DOI:https://doi.org/10.1007/s00702-020-02230-x
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Freie Schlagwort(e):Alzheimer’s disease; COVID-19; Parkinsonism; Parkinson’s disease; SARS-CoV-2 brain disorders; brain bank; brain pathology; brain stem; cardiorespiratory centre; cognitive dysfunction; coronavirus; depression; movement disorders; multiple sclerosis; neuroinvasion; neurological symptoms/disorders; neuroprotection; postmortem studies; therapy
Datum der Freischaltung:19.04.2024
Datum der Erstveröffentlichung:01.09.2020
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International